Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04851964 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
A Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
- 20
- Study locations
NCT04851964 is a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps that has completed, run by AstraZeneca. The registered enrollment target is 416 participants, above the 105-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (296% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT04851964, a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Experimental: Tezepelumab
- DRUG Mometasone furoate or equivalent intranasal corticosteroid
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - Newport Beach
- Research Site - Roseville
- Research Site - Walnut Creek
Colorado
- Research Site - Colorado Springs
- Research Site - Denver
Maryland
- Research Site - Baltimore
- Research Site - White Marsh
Alabama
- Research Site - Birmingham
Florida
- Research Site - Boca Raton
Illinois
- Research Site - Chicago
Massachusetts
- Research Site - Boston
Missouri
- Research Site - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2024-12-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04851964
The ClinicalTrials.gov registry entry for NCT04851964 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 105-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (296% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04851964 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT04851964 about?
NCT04851964 is a clinical study titled "Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis". A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis
What is the current status of trial NCT04851964?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2021-04-22. Estimated completion is 2024-12-11.
What conditions does trial NCT04851964 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps.
What interventions are being tested in trial NCT04851964?
The interventions under investigation include: Placebo (OTHER), Experimental: Tezepelumab (BIOLOGICAL), Mometasone furoate or equivalent intranasal corticosteroid (DRUG).
Who is sponsoring clinical trial NCT04851964?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04851964 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Rhinosinusitis With Nasal Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
-
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
RECRUITING · Phase 3
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
-
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
RECRUITING · Phase 2
-
The Role of IL5 in Epithelial Cell Integrity
RECRUITING · Early Phase 1
-
3D Printing to Improve Nasal Irrigation Outcome
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.